Last reviewed · How we verify
JNJ-63623872
At a glance
| Generic name | JNJ-63623872 |
|---|---|
| Also known as | 14C-JNJ-63623872 |
| Sponsor | Janssen Cilag N.V./S.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications (PHASE3)
- A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872 (PHASE1)
- A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation (PHASE1)
- A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment (PHASE1)
- A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants (PHASE1)
- A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment (PHASE1)
- Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-63623872 CI brief — competitive landscape report
- JNJ-63623872 updates RSS · CI watch RSS
- Janssen Cilag N.V./S.A. portfolio CI